1921
Volume 85, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

All the records from the Spanish information system for hospital data of patients diagnosed with leishmaniasis during a 12-year period (1997–2008) were studied. The 2,028 individuals were hospitalized because of leishmaniasis, as indicated by the principal diagnostic code. The average hospitalization rate was 0.41/100,000 inhabitants. One-third of them were co-infected with human immunodeficiency virus (HIV). The incidence of hospitalization in the adult population with leishmaniasis co-infected with HIV increased with age, peaked at 35–39 years of age and subsequently declined. In the pediatric population, all leishmaniasis cases occurred in HIV-negative children. Incidence of hospitalizations was highest in Madrid and in the Mediterranean coast. The cost per inpatient hospital care was $9,601 corresponding to an annual direct cost of more than $1.5 million for inpatient care alone. The economical burden of leishmaniasis is not neglectable and in the 12-year study period it represented more than $19 million.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2011.11-0310
2011-11-01
2020-07-06
Loading full text...

Full text loading...

/deliver/fulltext/14761645/85/5/820.html?itemId=/content/journals/10.4269/ajtmh.2011.11-0310&mimeType=html&fmt=ahah

References

  1. WHO, 2010. Leishmaniasis. Available at: http://www.who.int/topics/leishmaniasis/en/. Accessed July 25, 2010.
    [Google Scholar]
  2. Alvar J, 2001. Leishmaniasis: from boilogy to control. Second edition. Salamanca: Laboratorios Intervet S.A.
    [Google Scholar]
  3. Desjeux P, Alvar J, 2003. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97 (Suppl 1): 315.[Crossref]
    [Google Scholar]
  4. Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J, 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334359.[Crossref]
    [Google Scholar]
  5. Tortajada C, Pérez-Cuevas B, Moreno A, Martínez E, Mallolas J, García F, Valls E, Miró JM, De Lazzari E, Gatell JM, 2002. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr 30: 364366.[Crossref]
    [Google Scholar]
  6. López-Vélez R, Casado JL, Pintado V, 2001. Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clin Microbiol Infect 7: 394395.[Crossref]
    [Google Scholar]
  7. Mira JA, Corzo JE, Rivero A, Macias J, De Leon FL, Torre-Cisneros J, Gomez-Mateos J, Jurado R, Pineda JA, 2004. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 70: 298301.
    [Google Scholar]
  8. World Health Assembly, 2007. Control of leishmaniasis. 60th World Health Assembly, 9th plenary meeting, 21 May 2007. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA60/A60_R13-en.pdf. Accessed April 11, 2011.
    [Google Scholar]
  9. Bern C, Maguire JH, Alvar J, 2008. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2: e313.[Crossref]
    [Google Scholar]
  10. Ministerio de Sanidad y Consumo, 2010. International Classification of Diseases 9th revision Clinical Modification. Available at: http://www.msc.es/estadEstudios/estadisticas/normalizacion/clasifEnferm/instrucNorma.htm. Accessed March 22, 2011.
    [Google Scholar]
  11. National Health Insurance, 2002. Deputy Directors Office of Administrative Coordination. National Information System for Hospital Data (CMBD) INSALUD hospitals 2001. Madrid, Spain. Available at: www.ingesa.msc.es/. Accessed March 22, 2011.
    [Google Scholar]
  12. Rivero Cuadrado A., 2000. The minimum data set in the NHS: early and ongoing developments. Rev Fuentes Estadísticas 49:1819. Available at: http://www.webcitation.org/query.php?url=http://www.fuentesestadisticas.com/Numero49/Paginas/18-19.htm&refdoi=10.1186/1471-2458-8-109. Accessed January 20, 2010.
    [Google Scholar]
  13. Gil Prieto R, San Román Montero J, Gómez Alejandre C, Alvaro Meca LA, Rivero A, Gil de Miguel A, 2009. Epidemiology of pneumococcal meningitis hospitalizations in pediatric population in Spain (1998–2006). Vaccine 27: 26692673.[Crossref]
    [Google Scholar]
  14. Schreyögg J, Stargardt T, Tiemann O, Busse R, 2006. Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries. Health Care Manage Sci 9: 215223.[Crossref]
    [Google Scholar]
  15. Valcárcel Y, Bastero R, Anegón M, González S, Gil A, 2008. The epidemiology of hospital admissions due to leishmaniasis in Spain (1999–2003). Enferm Infecc Microbiol Clin 26: 278281.[Crossref]
    [Google Scholar]
  16. Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, Molina R, Moreno J, 1997. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10: 298319.
    [Google Scholar]
  17. CMBD, 2010. CMBD date. Available at: http://www.msc.es/en/estadEstudios/estadisticas/cmbdhome.htm. Accessed May 30, 2010.
    [Google Scholar]
  18. Kubar J, Marty P, Lelièvre A, Quaranta JF, Staccini P, Caroli-Bosc C, Le Fichoux Y, 1998. Visceral leishmaniasis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS 12: 21472153.[Crossref]
    [Google Scholar]
  19. Cruz I, Morales MA, Noguer I, Rodríguez A, Alvar J, 2002. Leishmania in discarded syringes from intravenous drug users. Lancet 359: 11241125.[Crossref]
    [Google Scholar]
  20. Bettini S, Gramiccia M, Gradoni L, Pozio E, Mugnai S, Maroli M, 1983. Leishmaniasis in Tuscany (Italy). VIII. Human population response to leishmanin in the focus of Monte Argentario (Grosseto) and epidemiological evaluation. Ann Parasitol Hum Comp 58: 539547.
    [Google Scholar]
  21. Marty P, Le Fichoux Y, Giordana D, Brugnetti A, 1992. Leishmanin reaction in the human population of a highly endemic focus of canine leishmaniasis in Alpes-Maritimes, France. Trans R Soc Trop Med Hyg 86: 249259.[Crossref]
    [Google Scholar]
  22. Acedo Sánchez C, Martín Sánchez J, Vélez Bernal ID, Sanchís Marín MC, Louassini M, Maldonado JA, Morillas Márquez F, 1996. Leishmaniasis eco-epidemiology in the Alpujarra region (Granada Province, southern Spain). Int J Parasitol 26: 303310.[Crossref]
    [Google Scholar]
  23. Alvar J, Cañavate C, Molina R, Moreno J, Nieto J, 2004. Canine leishmaniasis. Adv Parasitol 57: 188.[Crossref]
    [Google Scholar]
  24. Dedet JP, Pillot B, Gentilini M, 1991. Evaluation of the socioeconomic costs of cutaneous leishmaniasis in French Guiana. Rev Epidemiol Sante Publique 39: 129133.
    [Google Scholar]
  25. Peiro S, Librero J, 1999. The quality assessment from the minimum basic hospital discharge data set. Rev Neurol 29: 651661.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2011.11-0310
Loading
/content/journals/10.4269/ajtmh.2011.11-0310
Loading

Data & Media loading...

  • Received : 13 May 2011
  • Accepted : 01 Aug 2011
  • Published online : 01 Nov 2011
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error